Glycosylation News and Research

RSS

An overview of spike protein antigen COVID-19 vaccine candidates

A new paper in the journal Reviews in Medical Virology provides a perspective on current vaccine development strategies and tools, which may allow the production of safe and effective vaccines.

22 Feb 2021

Evolution of the spike gene of SARS-CoV-2 for human adaptation

Researchers have found a 96% similarity in nucleotide sequence between bat coronavirus (RaTG13), isolated from Rhinolophus affinis bats in China in 2013, and SARS-CoV-2 and ~97% amino acid similarity with the Spike (S) protein. This S protein performs two essential roles, i.e., mediates receptor-binding and membrane fusion. Hence, spike protein is regarded as a key coronavirus determinant of host tropism.

21 Feb 2021

O-glycosylation of SARS-CoV-2 spike protein in insect and human cell lines

The mapping of O-glycosites requires instruments that can support electron transfer dissociation (ETD) fragmentation. In a new study published on the bioRxiv preprint server, researchers report their results on whether O-glycosylation patterns affect immunogens for vaccine development.

18 Feb 2021

A glycan controls how SARS-CoV-2’s spike protein opens, study finds

Using simulations, a team of researchers in the U.S. found that the glycan at position N343 of the SARS-CoV-2 spike protein’s receptor-binding domain (RBD) helps in its opening. A mechanism that aids its binding to the host cell receptor.

18 Feb 2021

SARS-CoV-2 D614G mutation associated with lower antibody binding

The onset of the COVID-19 pandemic has brought about an international effort to uncover the biology of its causative agent, SARS-CoV-2, and to develop effective and safe antivirals to contain and treat the infection. A new study by a team of researchers in France and Sweden discusses one such study, exploring the relative immunogenicity of the three main structural proteins of the virus.

18 Feb 2021

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

A new preprint research paper posted to the bioRxiv server demonstrates the potential of using the pre-existing protective responses to produce a broad-spectrum neutralizing response against not just SARS-CoV-2 but other future pathogens.

14 Feb 2021

New mouse model of SARS-CoV-2 infection reflects features of human infection

Now, a new preprint research paper posted to the bioRxiv server reports the development of a modified mouse model that allows productive SARS-CoV-2 infection of the mouse lungs, as well as the exploration of type I and III interferon responses in this condition.

14 Feb 2021

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Feb 2021

New research aims to explore functions of bile acids in the gut stem cell niche

Examining gut health from a different angle, Flinders University’s Associate Professor Robyn Meech is looking at what can trigger colon cancer – and she believes bile acids may provide a significant piece of the puzzle.

12 Feb 2021

Inhibition of protein glycosylation successfully prevents SARS-CoV-2 infection in vitro

A new study provides direct evidence that the oligosaccharides attached to the viral surface spike protein are essential for viral infection, offering new approaches to preventive and therapeutic drugs.

9 Feb 2021

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

A new preprint posted to the bioRxiv server demonstrates that similar mucins and mucin-like proteins cannot only suppress HIV-1 infectivity via blockage of viral attachment to the host cells but can block infection by multiple enveloped viruses.

4 Feb 2021

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

A new study server reports highly protective neutralizing monoclonal antibodies against the SARS-CoV-2.

4 Feb 2021

Genetic interactions may shed light on NGLY1 deficiency

In 2012, four-year-old Bertrand Might became the first-ever patient diagnosed with a rare genetic disorder called N-glycanase (NGLY1) deficiency. The discovery of this condition and Bertrand's diagnosis allowed doctors to look for other children with the same genetic defect. Since then, more than 60 additional patients have been found.

26 Jan 2021

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

With the emergence of COVID-19 (coronavirus disease 2019), researchers have been closely investigating the complex interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the human immune system, and COVID-19 disease severity.

25 Jan 2021

Researchers use SARS-CoV-2 to bioengineer universal vaccine platform

Using SARS-CoV-2, a team of scientists from the United States has recently developed a bioengineered bacteriophage T4 nanoparticle structure using CRISPR technology that can be used as a universal platform to produce vaccines.

21 Jan 2021

Researchers develop new method for charting SARS-CoV-2 spike protein glycosylation

Researchers develop a novel, simple and affordable method for N-glycan fingerprinting based on enzymatic fluorescent glycan labeling and electrophoresis. This new method may help us understand important changes in glycosylation in the SARS-CoV-2 spike protein – something which could inform future therapeutic research.

20 Jan 2021

SARS-CoV-2 anti-N rigid monoclonal antibodies provide accurate early diagnosis

An interesting new preprint research paper that was posted on the bioRxiv* server recently describes the use of rigid monoclonal antibodies (mAbs) in contrast to flexible mAbs, and how this affects the binding of multiple mAbs to the same antigen.

17 Jan 2021

A high-temperature tolerant SARS-CoV-2 derived immunogen as a potential vaccine candidate

There have been significant efforts worldwide to combat COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One prominent strategy has been to develop vaccines against the virus. Numerous vaccine candidates are under development, and a handful have now been approved for use by several countries.

17 Jan 2021

Antibody-Fc-mediated innate immunity shapes COVID-19 severity

A short paper that appeared recently on the preprint bioRxiv server pointed to a link between specific characteristics of anti-SARS-CoV-2 antibodies associated with the severity of COVID-19.

12 Jan 2021

Researchers discover new metabolic vulnerability in a highly aggressive form of lung cancer

Researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC).

5 Jan 2021

Glycosylation News and Research

An overview of spike protein antigen COVID-19 vaccine candidates

Evolution of the spike gene of SARS-CoV-2 for human adaptation

O-glycosylation of SARS-CoV-2 spike protein in insect and human cell lines

A glycan controls how SARS-CoV-2’s spike protein opens, study finds

SARS-CoV-2 D614G mutation associated with lower antibody binding

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

New mouse model of SARS-CoV-2 infection reflects features of human infection

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

New research aims to explore functions of bile acids in the gut stem cell niche

Inhibition of protein glycosylation successfully prevents SARS-CoV-2 infection in vitro

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

Genetic interactions may shed light on NGLY1 deficiency

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

Researchers use SARS-CoV-2 to bioengineer universal vaccine platform

Researchers develop new method for charting SARS-CoV-2 spike protein glycosylation

SARS-CoV-2 anti-N rigid monoclonal antibodies provide accurate early diagnosis

A high-temperature tolerant SARS-CoV-2 derived immunogen as a potential vaccine candidate

Antibody-Fc-mediated innate immunity shapes COVID-19 severity

Researchers discover new metabolic vulnerability in a highly aggressive form of lung cancer

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News